Evidence Hub

Bullous Pemphigoid Induced by Cefixime: A Rare Side Effect

Nicolas Sandakly, Georgio El Koubayati, H. Nassereddine, Fady Haddad

Cureus, 2024

Abstract

Bullous pemphigoid (BP) is the most prevalent autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and manifests with pruritus and localized or, most commonly, generalized bullous lesions. Numerous studies have established the association between BP and oral antidiabetic agents, particularly dipeptidyl peptidase 4 (DPP4) inhibitors, diuretics, and certain antibiotics, notably levofloxacin and cephalexin. In this report, we present a case of an 85-year-old female who presented with diffuse vesicles and bullae on her trunk and extremities five days after completing a four-week course of cefixime for pyelonephritis. Clinical examination and histopathological analysis confirmed the diagnosis of BP. The patient responded well to topical and systemic corticosteroids. This article presents the first documented case of BP induced by cefixime and underscores the importance of considering medication-induced BP in elderly patients presenting with blistering eruptions.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free